APTV vs TSLA

The deterministic health scores present a mixed picture: the Piotroski F-Score of 4/9 indicates stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite a high current P/E of 58.82, the forward P/E of 9.01 suggests strong earnings growth expectations. The company beats earnings estimates consistently, with a 3/4 beat rate over the last four quarters and an average surprise of 14.89%, yet insider selling and weak long-term price performance raise caution. While analysts are bullish with a $101.81 target price and a 'buy' recommendation, the stock trades at a significant premium to the Graham Number of $35.41, implying high valuation risk.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.